Clinical Trials
11 trialsNCT07188090 2025-11-28
HSCT
Thomas Jefferson University
Phase 2 Recruiting
NCT02909036 2025-10-10
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT06520176 2024-07-25
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
The Affiliated People's Hospital of Ningbo University
Phase 3 Recruiting
NCT05338047 2023-02-28
Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Completed
NCT01355705 2018-09-18
Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Stanford University
Phase 1/2 Completed
NCT02488382 2017-10-17
Lonquek for Autologous Stem Cell Mobilization
Sheba Medical Center
Phase 1/2 Unknown
NCT02098109 2017-07-18
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Washington University School of Medicine
Phase 2 Completed
NCT00681044 2017-04-28
HD Melphalan and SCT in Patients With IGDD or LCDD
Boston Medical Center
Phase 2 Terminated
NCT01701076 2016-08-24
BRd
Cantonal Hospital of St. Gallen
Phase 2 Completed
NCT00526734 2013-08-12
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00067639 2012-08-01
Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed